Related Experiment Video
Updated: Mar 19, 2026
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure
Antuani R Baptistella1, Marcos Vinicios Salles Dias, Samuel Aguiar
1aInternational Research Center Departments of bPelvic Surgery cAnatomic Pathology, AC Camargo Cancer Center dNational Institute for Science and Technology on Oncogenomics - INCITO (CNPq/MCT/FAPESP), São Paulo, Brazil.
Abstract:
The A33 protein, expressed in colorectal tumors, is a target for improving treatment of patients with colorectal cancer. Over the last decade, studies have tested anti-A33 antibody as a therapeutic agent for these patients. Preclinical results were promising, but clinical trials did not confirm positive results. Here, immunohistochemistry in colorectal cancer tissue showed that samples from well-differentiated tumors presented a strong A33 membrane staining, whereas poorly differentiated tumors and mucinous adenocarcinomas showed weak cytoplasmic and nuclear staining. Moderately differentiated tumors presented variable staining. We suggest that in future clinical trials, patients should be selected on the basis of membrane expression of A33.
Insights
Targeting A33 protein in colorectal cancer shows promise. Patient selection based on A33 membrane expression in tumors is crucial for future therapeutic success in colorectal cancer treatment.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Diagnostics
Background:
- A33 protein is a potential therapeutic target in colorectal cancer.
- Anti-A33 antibody treatments showed promise pre-clinically but failed in clinical trials.
- Understanding A33 expression patterns is key to improving treatment efficacy.
Purpose of the Study:
- To investigate the expression patterns of A33 protein in different colorectal tumor subtypes.
- To correlate A33 expression with tumor differentiation.
- To inform patient selection for future anti-A33 antibody therapies.
Main Methods:
- Immunohistochemistry was used to analyze A33 protein expression in colorectal cancer tissues.
- Staining patterns (membrane, cytoplasmic, nuclear) were evaluated.
- Correlation with tumor differentiation (well, moderate, poor) and histology (mucinous adenocarcinoma) was assessed.
Main Results:
- Well-differentiated colorectal tumors exhibited strong A33 membrane staining.
- Poorly differentiated tumors and mucinous adenocarcinomas showed weak A33 staining (cytoplasmic and nuclear).
- Moderately differentiated tumors displayed variable A33 expression.
Conclusions:
- A33 protein expression varies significantly with colorectal tumor differentiation and histology.
- Membrane expression of A33 is a potential biomarker for patient selection.
- Future clinical trials should stratify patients based on A33 membrane expression for targeted therapy.
